智通财经APP获悉，百奥赛图-B(02315)涨超6%，截至发稿，涨6.24%，报59.6港元，成交额8729.41万港元。
消息面上，今年上半年，百奥赛图实现营收9.4亿元，同比增长51.6%；归母净利润2.4亿元，同比大增402%。报告期内，临床前板块总营收7.23亿元，同比增长57.9%，其中创新动物模型销售收入4.46亿元，同比增长62.4%；临床前药理药效评估收入2.43亿元，同比增长57.0%。与此同时，本月初，百奥赛图宣布与齐鲁制药达成全人纳米抗体分子非排他授权合作，支持神经领域创新药物开发。
中邮证券指出，行业景气度持续高涨叠加海外拓展共振，动物模型+临床前药效业务维持高增。申万宏源认为，公司形成以模式动物+千鼠万抗双轮发展的核心业务轴，深度布局国内外市场，凭借技术闭环+数据壁垒+全球化布局+AI赋能，有望成长为全球领先的抗体药物源头创新平台。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.